News

The warning comes after about 100 preliminary reports of Guillain-Barré cases occurred against a backdrop of about 12.5 million Johnson & Johnson doses administered, the FDA said in a statement ...
The Johnson & Johnson COVID-19 vaccine has been linked to Guillain Barré Syndrome in rare cases. Experts explain what to know about the condition.
According to the Mayo Clinic, Guillain-Barre syndrome (GBS) often begins with tingling and weakness in a person's feet and legs. Eventually, the tingling spreads to the upper body and arms.
The FDA has said that Johnson & Johnson’s COVID-19 vaccine may lead to an increased risk for Guillain-Barré syndrome. Perspectives from Ahmet Hoke, MD, PhD, FRCPC; Dhanashri P. Miskin, MD ...
About 100 preliminary reports of Guillain-Barré have been detected after 12.8 million doses of Johnson & Johnson vaccine were administered, the Centers for Disease Control and Prevention said in ...
The Johnson & Johnson COVID-19 vaccine will now include a U.S. Food and Drug Administration warning because of the chance of an increase in the risk for a rare neurological disorder.
The Johnson & Johnson COVID-19 vaccine will now include a U.S. Food and Drug Administration warning because of the chance of an increase in the risk for a ... known as Guillain-Barre syndrome, ...
The Johnson & Johnson COVID-19 vaccine will now include a U.S. Food and Drug Administration warning because of the chance of an increase in the risk for a ... known as Guillain-Barre syndrome, ...
The Johnson & Johnson COVID-19 vaccine will now include a U.S. Food and Drug Administration warning because of the chance of an increase in the risk for a rare neurological ...
The Johnson & Johnson COVID-19 vaccine will now include a U.S. Food and Drug Administration warning because of the chance of an increase in the risk for a rare neurological disorder.
The Johnson & Johnson COVID-19 vaccine will now include a U.S. Food and Drug Administration warning because of the chance of an increase in the risk for a rare neurological disorder.